Study Shows TRUDHESA™ Was Well Tolerated and Delivered Rapid, Consistent Symptom Relief Exploratory Patient-Reported Outcomes Data Indicated More Than One...
Top-line results from Phase IIb sepsis trial expected in Q2 2022Phase IIb trial in severe and critical COVID-19 patients planned...
PETACH TIKVA, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes...
Patent developed in collaboration with Syngene International LtdMINNEAPOLIS, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical...
Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) --...
Solution unifies scheduling, clearance, intake and payments to improve patient/provider experiences and drive financial performance MURRAY, Utah, Aug. 09, 2021...
MENLO PARK, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its...
Six-month priority review granted for DARE-BV1 with PDUFA target action date set for December 7, 2021.NDA supported by positive data...
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery...
InnerScope partners with Health-E Commerce to offer Medical-Grade Direct-to-Consumer Hearing Aids to the 70+ million consumers with pre-tax and tax-free...
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc.,...
Jeroen Grasman joins AltruBio with over 15 years' experience in biotech finance and operationsThe expansion of AltruBio’s management team will...
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine...
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company...
Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21Initiation of Phase...
Provides access to $30 million in capital contingent on FDA approval and U.S. market access for LibervantWARREN, N.J., Aug. 09,...
First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of...
Outlines anticipated milestones related to its DIMI and SAMI devicesTORONTO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”...
$200M received from BMS for anti-TIGIT bispecific antibody collaborationFDA cleared IND for AGEN1777 clinical enrollmentAGEN1181 rapidly advancing in the clinic;...
Mark Morgan Mark Morgan, SVP of Grail, newly appointed Board Member of Dante Labs CAMBRIDGE, United Kingdom, Aug. 09, 2021...
